Sarepta Therapeutics, Inc.
SRPT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000873303
No open-market purchases or sales by Sarepta Therapeutics, Inc. insiders were filed in the last 90 days; 337 institutions reported holding it in 13F filings for Q2 2026, worth $2.08B in total; Oaktree Capital is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −12 vs. previous quarter
- 337
- 13F valueReported value at the end of Q2 2026
- $2.08B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding SRPT, Q2 2026
1 superinvestor reports holding Sarepta Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Oaktree Capital
Howard Marks
0.1%
Sarepta Therapeutics, Inc.'s share of the portfolio
- Shares
- –
- Value
- $6.34M
Latest insider trades
Open-market purchases and sales by Sarepta Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 (view filing) | Mar 12 | 1 day | Mayo StephenDirector | SSale | −7.24K | $17.02 | −$123.2K | −80.4%1.76K after | |
| Dec 18, 2025 (view filing) | Dec 16 | 2 days | Estepan Ian MichaelChief Operating Officer | SSale | −13.2K | $22.31 | −$294.2K | −6.4%193.3K after | |
| Mar 13, 2025 (view filing) | Mar 12 | 1 day | Nicaise ClaudeDirector | SSale | −2.49K | $99.64 | −$248.2K | −8.2%27.8K after | |
| Dec 16, 2024 (view filing) | Dec 12 | 4 days | Wigzell Hans Lennart RudolfDirector | SSale | −10.5K | $124.84 | −$1.31M | −31.5%22.8K after | |
| Dec 6, 2024 (view filing) | Dec 5 | 1 day | Boor Kathryn JeanDirector | SSale | −1.64K | $125.55 | −$205.4K | −21.8%5.88K after | |
| Sep 3, 2024 (view filing) | Aug 30 | 4 days | Estepan Ian MichaelChief Financial Officer | SSale | −5.99K | $137.36 | −$822.1K | −15.0%33.9K after | |
| Aug 20, 2024 (view filing) | Aug 16 | 4 days | Chambers Michael AndrewDirector | PPurchase | +37.0K | $133.80 | +$4.96M | +15.0%284.0K after | 3 lots |
| Jun 25, 2024 (view filing) | Jun 25 | Same day | Brown Ryan EdwardEVP, General Counsel | SSale | −39.0K | $161.61 | −$6.30M | −69.5%17.1K after | 7 lots10b5-1 |
| Jun 25, 2024 (view filing) | Jun 24-25 | 1 day | Arif BilalChief Tech Ops Officer | SSale | −11.8K | $163.13 | −$1.92M | −40.4%17.4K after | 6 lots10b5-1 |
| May 6, 2024 (view filing) | May 2 | 4 days | Murray DallanChief Customer Officer | SSale | −3.63K | $140.00 | −$508.9K | −16.7%18.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Sarepta Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,994,958 | $341.3M | 0.01% | +4,239,681+28.7% | Added |
| State Street Corp | 8,916,090 | $160.2M | 0.00% | +2,302,776+34.8% | Added |
| Vanguard Portfolio Management LLC | 8,377,470 | $150.5M | 0.01% | +1,736,778+26.2% | Added |
| Two Sigma Investments, LP | 4,598,735 | $82.6M | 0.06% | +5,540+0.1% | Added |
| Vanguard Capital Management LLC | 4,591,755 | $82.5M | 0.00% | +13,520+0.3% | Added |
| First Trust Advisors LP | 4,365,951 | $78.5M | 0.05% | +230,163+5.6% | Added |
| AQR Capital Management LLC | 4,325,689 | $76.9M | 0.03% | −2,107,423−32.8% | Reduced |
| Geode Capital Management, LLC | 2,771,758 | $49.8M | 0.00% | +782,962+39.4% | Added |
| Highbridge Capital Management LLC | – | $49.3M | 1.68% | – | – |
| Erste Asset Management GmbH | 2,568,945 | $45.5M | 0.35% | −400,000−13.5% | Reduced |